deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT03009344

A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

A Phase 1 Study of Tazemetostat in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Sponsor: Eisai Co., Ltd.

Conditions Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Interventions Tazemetostat
Updated 16 times since 2017 Last updated: Apr 6, 2022 Started: Jan 10, 2017 Primary completion: Jul 12, 2017 Completion: Jun 17, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03009344, this PHASE1 trial focuses on Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma and remains completed. Sponsored by Eisai Co., Ltd., it has been updated 16 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Dec 2017 · 7 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~Mar 2020 · 14 months · monthly snapshot~Mar 2020 – ~Aug 2020 · 5 months · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Dec 2022 · 15 months · monthly snapshot~Dec 2022 – ~Jul 2024 · 19 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Dec 2022 — Jul 2024 [monthly]

    Completed PHASE1

  4. Sep 2021 — Dec 2022 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  5. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1

▶ Show 11 earlier versions

  1. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  2. Aug 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE1

  3. Mar 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE1

  4. Jan 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE1

  5. Nov 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE1

  6. Sep 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE1

  7. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE1

  8. Dec 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  9. May 2017 — Dec 2017 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  10. Feb 2017 — May 2017 [monthly]

    Not Yet Recruiting PHASE1

  11. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eisai Co., Ltd.
Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations